Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx – Endpoints News

October 24, 2017 by  
Filed under Alzheimers News

Sponsored By
Imprimis spins out a new biotech focused on eye drugs; Alzheimer's groups back PhII study at Amylyx
Endpoints News
The Alzheimer's Association and the Alzheimer's Drug Discovery Foundation are helping fund a new combination therapy for Alzheimer's by Amylyx Pharmaceuticals. Their $1.85 million grant will support a small Phase II study with 50 patients, who will be …
Innovative Alzheimer's Disease Combination Therapy Trial Supported By New Joint Funding InitiativeMarkets Insider

all 2 news articles »

More Info: Click here

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

*